S&P 500   4,387.45 (-0.51%)
DOW   34,427.60 (+0.18%)
QQQ   350.67 (-0.74%)
AAPL   161.25 (-0.23%)
MSFT   292.40 (-1.34%)
FB   303.84 (-1.58%)
GOOGL   2,566.76 (-1.89%)
AMZN   2,814.11 (-2.66%)
TSLA   940.26 (+1.10%)
NVDA   226.23 (-3.20%)
BABA   120.49 (+0.10%)
NIO   24.31 (-2.25%)
AMD   112.81 (-3.19%)
CGC   7.47 (+0.95%)
MU   81.69 (-1.52%)
GE   92.19 (-4.87%)
T   26.56 (+0.84%)
F   20.25 (-0.69%)
DIS   137.20 (-0.19%)
AMC   16.25 (-2.34%)
PFE   52.63 (+2.11%)
ACB   4.27 (-1.16%)
BA   204.94 (+0.36%)
S&P 500   4,387.45 (-0.51%)
DOW   34,427.60 (+0.18%)
QQQ   350.67 (-0.74%)
AAPL   161.25 (-0.23%)
MSFT   292.40 (-1.34%)
FB   303.84 (-1.58%)
GOOGL   2,566.76 (-1.89%)
AMZN   2,814.11 (-2.66%)
TSLA   940.26 (+1.10%)
NVDA   226.23 (-3.20%)
BABA   120.49 (+0.10%)
NIO   24.31 (-2.25%)
AMD   112.81 (-3.19%)
CGC   7.47 (+0.95%)
MU   81.69 (-1.52%)
GE   92.19 (-4.87%)
T   26.56 (+0.84%)
F   20.25 (-0.69%)
DIS   137.20 (-0.19%)
AMC   16.25 (-2.34%)
PFE   52.63 (+2.11%)
ACB   4.27 (-1.16%)
BA   204.94 (+0.36%)
S&P 500   4,387.45 (-0.51%)
DOW   34,427.60 (+0.18%)
QQQ   350.67 (-0.74%)
AAPL   161.25 (-0.23%)
MSFT   292.40 (-1.34%)
FB   303.84 (-1.58%)
GOOGL   2,566.76 (-1.89%)
AMZN   2,814.11 (-2.66%)
TSLA   940.26 (+1.10%)
NVDA   226.23 (-3.20%)
BABA   120.49 (+0.10%)
NIO   24.31 (-2.25%)
AMD   112.81 (-3.19%)
CGC   7.47 (+0.95%)
MU   81.69 (-1.52%)
GE   92.19 (-4.87%)
T   26.56 (+0.84%)
F   20.25 (-0.69%)
DIS   137.20 (-0.19%)
AMC   16.25 (-2.34%)
PFE   52.63 (+2.11%)
ACB   4.27 (-1.16%)
BA   204.94 (+0.36%)
S&P 500   4,387.45 (-0.51%)
DOW   34,427.60 (+0.18%)
QQQ   350.67 (-0.74%)
AAPL   161.25 (-0.23%)
MSFT   292.40 (-1.34%)
FB   303.84 (-1.58%)
GOOGL   2,566.76 (-1.89%)
AMZN   2,814.11 (-2.66%)
TSLA   940.26 (+1.10%)
NVDA   226.23 (-3.20%)
BABA   120.49 (+0.10%)
NIO   24.31 (-2.25%)
AMD   112.81 (-3.19%)
CGC   7.47 (+0.95%)
MU   81.69 (-1.52%)
GE   92.19 (-4.87%)
T   26.56 (+0.84%)
F   20.25 (-0.69%)
DIS   137.20 (-0.19%)
AMC   16.25 (-2.34%)
PFE   52.63 (+2.11%)
ACB   4.27 (-1.16%)
BA   204.94 (+0.36%)
NASDAQ:TIL

Instil Bio Stock Forecast, Price & News

$12.29
-1.12 (-8.35%)
(As of 01/25/2022 02:54 PM ET)
Add
Compare
Today's Range
$11.70
▼
$13.57
50-Day Range
$12.61
▼
$22.33
52-Week Range
$11.43
▼
$29.49
Volume
31,266 shs
Average Volume
351,073 shs
Market Capitalization
$1.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive TIL News and Ratings via Email

Sign-up to receive the latest news and ratings for Instil Bio and its competitors with MarketBeat's FREE daily newsletter.


Instil Bio logo

About Instil Bio

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 (FOLR1) with indications, including gynecological, non-small cell lung cancer, and others. The company was incorporated in 2018 and is based in Dallas, Texas.

Headlines

Instil Bio Enters Oversold Territory (TIL)
January 13, 2022 |  nasdaq.com
Instil Bio Inc Shares Close the Week 22.3% Lower - Weekly Wrap
January 11, 2022 |  nasdaq.com
Instil Bio Inc Shares Approach 52-Week Low - Market Mover
January 8, 2022 |  nasdaq.com
Instil Bio Announces Poster Presentations at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 15, 2021 |  finance.yahoo.com
Instil Bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 15, 2021 |  finance.yahoo.com
Was The Smart Money Right About Instil Bio, Inc. (TIL)?
November 10, 2021 |  finance.yahoo.com
Instil Bio to Present at Upcoming Investor Conferences in November
November 8, 2021 |  finance.yahoo.com
Instil Bio Inc Shares Close the Day 12.3% Lower - Daily Wrap
September 30, 2021 |  nasdaq.com
Instil Bio Presents Subset Analysis of Patients with Checkpoint-Refractory Advanced Melanoma from Compassionate Use Study at 2021 ESMO Congress
September 16, 2021 |  finance.yahoo.com
Why Iovance Is Up Nearly 11% Today
September 15, 2021 |  finance.yahoo.com
BRIEF-Instil Bio Gets Clearance For Phase 2 Trial For Patients With Advanced Melanoma
September 13, 2021 |  msn.com
Instil Bio Receives IND Clearance to Initiate a Phase 2 Clinical Trial for Patients with Advanced Melanoma
September 13, 2021 |  finance.yahoo.com
Instil Bio to Present at Upcoming Investor Conferences in September
September 2, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TIL
Previous Symbol
CUSIP
N/A
CIK
1625584
Web
www.tillcap.com
Phone
240-676-3715
Fax
N/A
Employees
150
Year Founded
N/A

Sales & Book Value

Annual Sales
$140 thousand
Price / Sales
11,317.95
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
$-37.74 million
Net Margins
N/A
Pretax Margin
-159,803.86%
Return on Equity
-25.48%
Return on Assets
-20.32%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
16.30
Quick Ratio
16.30

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
128,927,000
Free Float
N/A
Market Cap
$1.58 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
11/15/2021
Today
1/25/2022
Next Earnings (Estimated)
2/21/2022
Fiscal Year End
12/31/2022

MarketRank™

Overall MarketRank™

1.75 out of 5 stars

Medical Sector

902nd out of 1,416 stocks

Biological Products, Except Diagnostic Industry

137th out of 206 stocks

Analyst Opinion: 3.4Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -












Instil Bio (NASDAQ:TIL) Frequently Asked Questions

Is Instil Bio a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Instil Bio in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Instil Bio stock.
View analyst ratings for Instil Bio or view top-rated stocks.

Are investors shorting Instil Bio?

Instil Bio saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 7,300,000 shares, an increase of 22.9% from the December 15th total of 5,940,000 shares. Based on an average daily volume of 521,700 shares, the days-to-cover ratio is presently 14.0 days. Approximately 12.1% of the shares of the stock are short sold.
View Instil Bio's Short Interest.

When is Instil Bio's next earnings date?

Instil Bio is scheduled to release its next quarterly earnings announcement on Monday, February 21st 2022.
View our earnings forecast for Instil Bio.

How were Instil Bio's earnings last quarter?

Instil Bio, Inc. (NASDAQ:TIL) issued its quarterly earnings results on Monday, November, 15th. The company reported ($0.33) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.32) by $0.01.
View Instil Bio's earnings history.

What price target have analysts set for TIL?

5 analysts have issued 12-month price targets for Instil Bio's shares. Their forecasts range from $23.00 to $34.00. On average, they expect Instil Bio's share price to reach $30.00 in the next twelve months. This suggests a possible upside of 144.1% from the stock's current price.
View analysts' price targets for Instil Bio or view top-rated stocks among Wall Street analysts.

Who are Instil Bio's key executives?

Instil Bio's management team includes the following people:
  • Mr. Bronson Crouch, Chairman & CEO (Age 48, Pay $2.37M)
  • Dr. Sandeep Laumas M.D., CFO & Chief Bus. Officer (Age 52, Pay $639.18k)
  • Dr. Zachary Roberts M.D., Ph.D., Chief Medical Officer (Age 43, Pay $810.69k)
  • Dr. Vijay Chiruvolu M.B.A., Ph.D., Chief Technical Officer (Age 59)

What other stocks do shareholders of Instil Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Instil Bio investors own include Bausch Health Companies (BHC), Saul Centers (BFS), Virtus LifeSci Biotech Products ETF (BBP), BB Healthcare Trust (BBH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), StoneCastle Financial (BANX), Yamana Gold (AUY), A. O. Smith (AOS), Sphere 3D (ANY) and Andersons (ANDE).

When did Instil Bio IPO?

(TIL) raised $250 million in an initial public offering on Friday, March 19th 2021. The company issued 13,900,000 shares at $17.00-$19.00 per share. Morgan Stanley, Jefferies, Cowen and Truist Securities acted as the underwriters for the IPO.

What is Instil Bio's stock symbol?

Instil Bio trades on the NASDAQ under the ticker symbol "TIL."

How do I buy shares of Instil Bio?

Shares of TIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Instil Bio's stock price today?

One share of TIL stock can currently be purchased for approximately $12.29.

How much money does Instil Bio make?

Instil Bio has a market capitalization of $1.58 billion and generates $140 thousand in revenue each year.

How many employees does Instil Bio have?

Instil Bio employs 150 workers across the globe.

What is Instil Bio's official website?

The official website for Instil Bio is www.tillcap.com.

Where are Instil Bio's headquarters?

Instil Bio is headquartered at CONTINENTAL BUILDING 25 CHURCH STREET, HAMILTON D0, HM1Z.

How can I contact Instil Bio?

Instil Bio's mailing address is CONTINENTAL BUILDING 25 CHURCH STREET, HAMILTON D0, HM1Z. The company can be reached via phone at 240-676-3715 or via email at [email protected].


This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.